Benralizumab
BiologicalBenralizumab subcutaneously on study week 0 until study week 44 inclusive.
NCT Number: NCT01928771
The purpose of this study is to determine whether Benralizumab reduces the number of asthma exacerbations in patients who remain uncontrolled on high doses of ICS-LABA.
Looking for future studies?
Notify Me12 year–75 year
All sexes
Interventional
Phase 3
Research Site, Bedford Park, Australia
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Benralizumab subcutaneously on study week 0 until study week 44 inclusive.
Placebo subcutaneously on study week 0 until study week 44 inclusive.
Time frame: Immediately following the first administration of study drug through Study Week 48.
The annual exacerbation rate is based on unadjudicated annual exacerbation rate reported by the investigator in the eCRF
Time frame: Immediately following the first administration of study drug through Study Week 48.
The annual exacerbation rate is based on unadjudicated annual exacerbation rate reported by the investigator in the eCRF
Time frame: Immediately following the first administration of study drug through Study Week 48.
The annual exacerbation rate associated with an emergency room visit or a hospitalization (adjudicated)
Time frame: Immediately following the first administration of study drug through Study Week 48.
Time frame: Immediately following the first administration of study drug through Study Week 48.
Time frame: Immediately following the first administration of study drug through Study Week 48.
Time frame: Immediately following the first administration of study drug through Study Week 48.
Time frame: Immediately following the first administration of study drug through Study Week 48.
Asthma symptoms during night time and daytime are recorded by the patient in the asthma daily diary. Symptom score values are from 0 (No asthma symptom) to 3 (unable to sleep because of asthma, or unable to do normal activities due to asthma), and total asthma symptom score is the sum of the daytime and night time score (0 to 6). Lower score (0) is indicating better asthma symptom, while higher score (6) is indicating worse asthma symptom. Baseline is defined as the average of data collected from the evening of study day -10 to the morning of study day 1. Each time point is calculated as bi-weekly means based on daily diary data. If more than 50% of scores are missing in a 14 day period then this is considered as missing. Symptom score lower is better.
Time frame: Immediately following the first administration of study drug through Study Week 48.
Asthma symptoms during night time and daytime are recorded by the patient in the asthma daily diary. Symptom score values are from 0 (No asthma symptom) to 3 (unable to sleep because of asthma, or unable to do normal activities due to asthma), and total asthma symptom score is the sum of the daytime and night time score (0 to 6). Lower score (0) is indicating better asthma symptom, while higher score (6) is indicating worse asthma symptom. Baseline is defined as the average of data collected from the evening of study day -10 to the morning of study day 1. Each time point is calculated as bi-weekly means based on daily diary data. If more than 50% of scores are missing in a 14 day period then this is considered as missing. Symptom score lower is better.
Time frame: Immediately following the first administration of study drug through Study Week 48.
Change from baseline to week 48 in number of rescue medication use (puffs/day)
Time frame: Immediately following the first administration of study drug through Study Week 48.
Change from baseline to week 48 in home lung function morning peak expiratory flow [PEF]
Time frame: Immediately following the first administration of study drug through Study Week 48.
Change from baseline to week 48 in home lung function evening peak expiratory flow [PEF]
Time frame: Immediately following the first administration of study drug through Study Week 48.
Change from baseline to Week 48 on proportion of night awakening due to asthma
Time frame: Immediately following the first administration of study drug through Study Week 48.
ACQ-6 contains one bronchodilator question and 5 symptom questions. Questions are rated from 0 (totally controlled) to 6 (severely uncontrolled). Mean ACQ-6 score is the average of the responses. Mean scores of <=0.75 indicates well-controlled asthma, scores between 0.75 to <=1.5 indicate partly controlled asthma, and >1.5 indicates not well controlled asthma.
Time frame: Immediately following the first administration of study drug through Study Week 48.
ACQ-6 contains one bronchodilator question and 5 symptom questions. Questions are rated from 0 (totally controlled) to 6 (severely uncontrolled). Mean ACQ-6 score is the average of the responses. Mean scores of <=0.75 indicates well-controlled asthma, scores between 0.75 to <=1.5 indicate partly controlled asthma, and >1.5 indicates not well controlled asthma.
Time frame: Baseline, week 4, week 4 day 6, week 8, week 16, week 24, week 32, week 40, week 48, week 56
Mean PK concentrations at each visit
Time frame: Pre-treatment until end of follow-up
Anti-drug antibodies (ADA) responses at baseline and post baseline. Persistently positive is defined as positive at >=2 post baseline assessments (with >=16 weeks between the first and the last positive) or positive at last post baseline assessment. Transiently positive is defined as having at least one post baseline ADA positive assessment and not fulfilling the conditions of persistently positive.
Time frame: Immediately following the first administration of study drug through Study Week 48.
Extend of exposure is defined as duration of treatment in days
Time frame: Immediately following the first administration of study drug through Study Week 48.
AQLQ(S)+12 overall score is defined as the average of all 32 questions in the AQLQ(S)+12 questionnaire. AQLQ(S)+12 is a 7-point scale questionnaire, ranging from 7 (no impairment) to 1 (severe impairment). Total or domain score change of >=0.5 are considered clinically meaningful.
Time frame: Immediately following the first administration of study drug through Study Week 48.
EQ-5D-5L VAS is to rate current health status on a scale of 0-100, with 0 being the worst imaginable health state.
Time frame: Immediately following the first administration of study drug through Study Week 48.
WPAI+CIQ (Work Productivity and Activity Impairment plus Classroom Impairment Questionnaire) contains 10 questions. Work productivity loss is derived by sum of percentage of missed work due to asthma and product of percentage of actual working hours times degree of asthma affecting work productivity while working. Percentage of missed work due to asthma is calculated by number of hours missed work due to asthma divided by total number of hours missed work plus number of hours actually worked. The work productivity loss is only applicable to patients who employed, which is only subset of the study population.
Time frame: Immediately following the first administration of study drug through Study Week 48.
WPAI+CIQ (Work Productivity and Activity Impairment plus Classroom Impairment Questionnaire) contains 10 questions. Classroom productivity loss is derived by sum of percentage of missed classes due to asthma and product of percentage of actual hours attending classes times degree of asthma affecting classroom productivity. Percentage of missed classes due to asthma is calculated by number of hours missed classes due to asthma divided by total number of hours missed classes plus number of hours actually attending classes. This is only applicable to patients who attending classes
Time frame: Immediately following the first administration of study drug through Study Week 48.
Time frame: Immediately following the first administration of study drug through Study Week 48
CGIC (Clinical global impression of change), and PGIC (Patient global impression of change) are overall evaluation of response to treatment, conducted separately by investigator and patient using 7-point rating scale, ranging from 1 (very much improved), to 7 (very much worse). This is additional measures collected after second Amendment, thus not all patients had data to be analyzed.
AstraZeneca
Industry
A Multicentre, Randomized, Double-blind, Parallel Group, Placebo-controlled, Phase III Efficacy and Safety Study of Benralizumab (MEDI-563) Added to High-dose Inhaled Corticosteroid Plus Long-acting β2 Agonist in Patients With Uncontrolled Asthma
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06644924
Asthma, Bronchial Diseases
Encinitas, California, United States
View Trial DetailsNCT05685381
Asthma, Bronchial Diseases
Beacon, New York, United States
View Trial DetailsNCT03186209
Asthma, Bronchial Diseases
Baotou, China
View Trial DetailsNCT02702687
Asthma, Bronchial Diseases
The Bronx, New York, United States
View Trial Details